RxDoctor Payments Data

Nancy Rist, MD

Internal Medicine · Aston, PANPI 1194885400

Payments from drug & device makers

$538in general payments, 2019–2025

Across 33 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$111
  • Daiichi Sankyo Inc.$64
  • Merck$54
  • GSK$34
  • Biohaven Pharmaceuticals, Inc.$34
  • Topcon Healthcare Solutions, Inc.$33
  • plus $207 from 11 others

What the payments were for

  • Food & beverage$537100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$538 in reported general payments places this provider in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$191,031
Medicare patients
585
Services billed
1,656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin91$113,068
EliquisApixaban84$108,138
OzempicSemaglutide78$106,932
FarxigaDapagliflozin Propanediol60$54,224
TrulicityDulaglutide30$49,746
XareltoRivaroxaban26$38,785
MounjaroTirzepatide27$37,999
JanuviaSitagliptin Phosphate22$28,668
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$25,276
RybelsusSemaglutide14$21,062
MyrbetriqMirabegron25$19,798
LinzessLinaclotide21$15,150
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$14,404
Breo ElliptaFluticasone/Vilanterol25$13,693
Rosuvastatin Calcium812$13,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$111$127,99492 claims
Boehringer IngelheimJardiance$28$113,06891 claims
Lilly USA, LLCTrulicity, Mounjaro$26$87,74557 claims
AstraZenecaFarxiga, Symbicort$28$61,93477 claims
GSKTrelegy Ellipta, Breo Ellipta$34$38,96941 claims
Johnson & JohnsonXarelto$13$38,78526 claims
MerckJanuvia$54$28,66822 claims
AbbVieLinzess, Synthroid$30$20,65487 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Aston

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →